It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.